Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis

Rheumatology (Oxford). 2021 Jul 1;60(7):3476-3477. doi: 10.1093/rheumatology/keab175.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
  • Antibodies, Antineutrophil Cytoplasmic
  • COVID-19*
  • Humans
  • Rituximab
  • SARS-CoV-2

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Rituximab